Gilead joins a lineup of Big Pharma partners betting big on TriNKETs, with a $300M cash ante to get started on a 5T4

Bill Haney’s Dragonfly Therapeutics is making the vault between biotech startup and the next big level: adding clinical-stage compounds to its own fledgling pipeline while welcoming another Big Pharma name to a lineup of industry partnerships that are now moving toward their own clinical destinies.